spacer
home > epc > Spring 2006
PUBLICATIONS

European Pharmaceutical Contractor

epc
Spring 2006
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC
   
Text
PDF
bullet
introduction
Dr Graham Hughes reviews this issue's tasty submissions in his Editor's Letter  
download pdf
bullet
Keynote
Established in 1958, the UK Code of Practice is one of the oldest in the global pharmaceutical sector, and provides a 'gold standard' for other industry codes throughout the world. Dr Richard Barker of the ABPI reports on the recent revisions and their implications, in Code Known  
download pdf
The symbiotic relationship that exists between the medical profession and the pharmaceutical industry is a fragile one. In Critical Concerns & Social Responsibility, Dr Otmar Kloiber of the World Medical Association reminds us that when communication breaks down, patients, physicians and the industry all suffer  
download pdf
In Time for Transparency, Dr Beat Widler of F. Hoffmann-La Roche Ltd considers the ethical obligation to disclose comprehensive information on clinical trial results - both positive and negative  
download pdf
bullet
Marketplace & Business
Cross-border compliance concerns continue to exercise the experts, as pharma outsources its operations and distributes to an ever-widening base of customers. Craig Wylie of BearingPoint ponders what's in store, in 2006: The Year of Compliance  
download pdf
To Outsource or Not - Is that Still the Question? Dr R Graham Hughes peers into his crystal ball to catch a glimpse of the prospects for contract research organisations  
download pdf
Times are changing fast. The focus of pharmaceutical research and development on finding new drugs is on the wane; today, the emphasis is put on innovation that extends the life cycle of a product. Guenther Illert at Capgemini reflects on the situation, in Pharma Feels the Strain  
download pdf
bullet
R&D Tax
Paul Harris of Ernst & Young looks at both the short-term and long-term trends playing out through R&D tax schemes in the UK, in Getting Back More Than Comic Relief  
download pdf
It is widely recognised that countries in which significant levels of R&D are conducted enjoy enhanced economic growth. David Cobb of Deloitte reports on the countries willing to reinvent themselves in order to make themselves more appealing to investors, in Competitive Regimes - R&D Global Scene  
download pdf
bullet
Legal & Regulatory
Regulatory requirements are being enforced more strongly than ever in order to protect the consumer: a fact evident with the recent expansion of the EU, where companies operating out of the former Eastern Bloc have to address these matters - and quickly. Carl Turner of Compliance Control weighs up Eastern Promise  
download pdf
Addicted to blockbusters? As the supply of big patents continues to shrink, Julian Hitchcock of Mills & Reeve wonders where pharma's new fix can come from, in Making Designer Drugs Pay  
download pdf
World's Health on High Alert - as the need for collective defences against infectious disease risks becomes greater, Linda Horton of Hogan & Hartson examines how the new international health regulations will affect global companies and governments alike  
download pdf
bullet
Clinical Research
In The Clinical Trial Hub, Dr Georg A Mathis of Appletree Ltd argues that the high quality of data and the cost effectiveness of trials make it well worth considering the inclusion of sites in CEE in any worldwide development plan  
download pdf
Today, pharma companies face the challenge of reaching an increasingly sophisticated customer - and in every country across the globe. It is, however, worth remembering the value of country-specific information notes Gary Muddyman of Conversis, in Back in the USSR  
download pdf
In order to remain competitive, service providers need to develop strategies suited to the sponsor's most pressing needs. In Staffing by Contract? Umakanta Sahoo and Rakesh Lalchandani at Chiltern International reveal that the key to the Indian approach is mutual benefit  
download pdf
bullet
Biomarkers & Drug Development
In The Rise of the Little 'Omics', Chris Beecher of Metabolon, Inc, explores how to get the most out of metabolomics for biomarker discovery - a young science with great potential 88 The use of biomarkers in clinical trials for documenting population changes is intended to support - indeed, eventually replace - other clinical observations. Dr Lawrence K Oliver at Mayo Clinical Trial Services discovers direct patient care can transform drug development, in Meet Your Marker  
download pdf
Faced with the possibility of a new breed of therapeutic abuse, sports testing laboratories may need to dramatically alter their working practices. The Intricacies of Detecting Gene Doping are asking serious questions of sport, concludes Phil Teale at HFL Ltd  
download pdf
bullet
Therapeutic Innovation
Each year 10.9 million people worldwide are diagnosed with cancer and 6.7 million die from it. In The Life & Times of Cancer (Research UK), Harpal S Kumar of Cancer Research UK discusses how the public sector must work more closely with the pharmaceutical industry to accelerate the development of new treatments from the lab to the clinic  
download pdf
Breathe Easy, Datamonitor's Shaun Falkingbridge assures us - developments are afoot to tackle the unmet need for adjustable dosing regimes that permit a temporary increase in drug dose during an asthma attack  
download pdf
bullet
Clinical Laboratories & Logistics
Dr Nick Crabb and Dr John Conti-Ramsden of Intertek reflect on an industry trend towards the practice of a more collaborative 'open innovation' approach to development at all stages of the drug pipeline, using analytical service organisations with advanced technical resources, in From Mission to Market  
download pdf
The drug development industry lags behind other high-tech segments that use tools such as product life cycle management to integrate their value-chains and partnerships with their suppliers and vendors. Dr Agostino Fede of PPD talks Central Labs and Sponsors: A Perfect Partnership?  
download pdf
Lost in Translation? As industry becomes increasingly global and good channels of communication prove ever more vital, Ted Marshall of Translution Limited gives computer-assisted solutions to translation issues a comprehension test  
download pdf
bullet
Reviews & Previews
With over 350 sessions and more than 1,000 speakers, the 42nd DIA Annual Meeting in Philadelphia, starting on the 18th June, provides the perfect opportunity for the global pharmaceutical community to talk shop  
download pdf
bullet
Data Management & IT Solutions
IT Today Transforms Clinical Trials' Tomorrow - Dr Max Horneck of clinIT AG believes that setting up a trial with IT provides the infrastructure required to answer the increasing challenges posed by changes in regulations  
download pdf
The average cost of developing new drugs and bringing them to market is now £350 million. Faced with this expense, pharmaceutical companies are increasing their efforts to contain development costs, argues Steve Beats of DRS Data Services Limited, in Hybrids Hit the Big Time  
download pdf
As the age of paper in clinical research comes to an end, Phil Lee of PHT Corporation asks whether the heir apparent is up to the job, in Why Go ePRO?  
download pdf
The way in which pharmaceutical companies choose to implement electronic document management can determine how effective their business becomes. Chris Dewey of Active Navigation considers the best way of Dealing with Documentation  
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field!
More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

Industry Events

Outsourcing in clinical Trial Medical Devices Europe 2018

7-8 February 2018, Munich, Germany

Outsourcing in Clinical Trials: Medical Devices Europe has now reached its fifth birthday. This event is focused on Medical devices. At this event you will learn about the new regulations, which were released this may, regarding medical devices in more detail, from speakers who are the heads in their respective fields.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement